Literature DB >> 30190836

Melanomas' fatal attraction to lysophosphatidic acid trails: a new prognostic and therapeutic approach?

Andrew J Muinonen-Martin1,1, Robert H Insall2,2.   

Abstract

Entities:  

Keywords:  cell migration; chemotaxis; lipid phosphate phosphatases; metastasis; pagetoid spread; signaling lipids

Year:  2015        PMID： 30190836      PMCID： PMC6094656          DOI： 10.2217/mmt.15.11

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  22 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

Review 2.  Chemotherapy for metastatic melanoma: time for a change?

Authors:  Helen J Gogas; John M Kirkwood; Vernon K Sondak
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

Review 3.  State of the art of diagnostic technology for early-stage melanoma.

Authors:  Pascale Guitera; Scott W Menzies
Journal:  Expert Rev Anticancer Ther       Date:  2011-05       Impact factor: 4.512

4.  Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.

Authors:  Ahmed Boucharaba; Claire-Marie Serre; Sandra Grès; Jean Sébastien Saulnier-Blache; Jean-Claude Bordet; Julien Guglielmi; Philippe Clézardin; Olivier Peyruchaud
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

5.  Molecular classification of cutaneous malignant melanoma by gene expression profiling.

Authors:  M Bittner; P Meltzer; Y Chen; Y Jiang; E Seftor; M Hendrix; M Radmacher; R Simon; Z Yakhini; A Ben-Dor; N Sampas; E Dougherty; E Wang; F Marincola; C Gooden; J Lueders; A Glatfelter; P Pollock; J Carpten; E Gillanders; D Leja; K Dietrich; C Beaudry; M Berens; D Alberts; V Sondak
Journal:  Nature       Date:  2000-08-03       Impact factor: 49.962

6.  The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.

Authors:  Ahmed Boucharaba; Claire-Marie Serre; Julien Guglielmi; Jean-Claude Bordet; Philippe Clézardin; Olivier Peyruchaud
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-12       Impact factor: 11.205

Review 7.  Pitfalls in the evaluation of melanocytic lesions.

Authors:  Thomas Brenn
Journal:  Histopathology       Date:  2011-12-16       Impact factor: 5.087

Review 8.  Melanoma prognostic factors found in the dermatopathology report.

Authors:  Michael J Payette; Marilyn Katz; Jane M Grant-Kels
Journal:  Clin Dermatol       Date:  2009 Jan-Feb       Impact factor: 3.541

9.  Protective effects of lysophosphatidic acid (LPA) on chronic ethanol-induced injuries to the cytoskeleton and on glucose uptake in rat astrocytes.

Authors:  Mónica Tomás; Francisco Lázaro-Diéguez; Juan M Durán; Pilar Marín; Jaime Renau-Piqueras; Gustavo Egea
Journal:  J Neurochem       Date:  2003-10       Impact factor: 5.372

10.  Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal.

Authors:  Andrew J Muinonen-Martin; Olivia Susanto; Qifeng Zhang; Elizabeth Smethurst; William J Faller; Douwe M Veltman; Gabriela Kalna; Colin Lindsay; Dorothy C Bennett; Owen J Sansom; Robert Herd; Robert Jones; Laura M Machesky; Michael J O Wakelam; David A Knecht; Robert H Insall
Journal:  PLoS Biol       Date:  2014-10-14       Impact factor: 8.029
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.